Orgaran (Danaparoid Sodium)

Danaparoid Sodium, the active ingredient in Orgaran, is a heparinoid presented as a injection for intravenous use. It prevents and treats venous thromboembolism and is used in patients undergoing orthopedic surgery, including knee and hip replacement procedures as well as other high‑risk immobilization scenarios.

GNH USA supplies Orgaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, including transplant centres, oncology centres, and specialty clinics, with a focus on quality assurance and regulatory compliance. The company adheres to WHO GMP standards and provides temperature‑controlled logistics where required.

Orgaran (danaparoid sodium) is indicated for anticoagulation in venous thromboembolism and related surgical settings.

Venous thromboembolism: prevents clot formation and facilitates treatment of existing clots. Deep vein thrombosis prophylaxis in orthopedic surgery: reduces risk of postoperative DVT. Heparin‑induced thrombocytopenia management: provides anticoagulation when heparin is contraindicated.

Common Side Effects: - Injection site bruising or pain. - Mild bleeding or hematoma. - Thrombocytopenia. - Nausea or headache. - Anemia. - Transient elevation of liver enzymes.

Serious or Rare Side Effects: - Severe or uncontrolled bleeding. - Adrenal hemorrhage. - Hypersensitivity reactions including anaphylaxis. - Paradoxical thrombosis. - Disseminated intravascular coagulation. - Severe skin necrosis.

Orgaran requires careful clinical monitoring due to its anticoagulant effect.

Renal impairment: adjust monitoring as drug clearance is renal. Bleeding risk: avoid use in patients with active major bleeding. Surgery: discontinue before major procedures to reduce hemorrhage. Concurrent anticoagulants: avoid combination therapy that may increase bleeding. Pregnancy: use only if potential benefit outweighs risk to fetus. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Orgaran may interact with several medications that affect hemostasis.

Major Interactions (Avoid): - Heparin: additive anticoagulant effect leading to severe bleeding. - Warfarin: increased INR and bleeding risk. - Direct oral anticoagulants (DOACs): overlapping anticoagulation. - Thrombolytics: heightened hemorrhage.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (aspirin, clopidogrel): increased bleeding risk. - NSAIDs: potential gastrointestinal bleeding. - Corticosteroids: may potentiate bleeding.